Spontaneous Regression of Diffuse Large B-cell Lymphoma in a Patient with Ataxia–Telangiectasia
暂无分享,去创建一个
[1] E. Sohrabi,et al. The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis , 2021, BMC Cancer.
[2] A. Koc,et al. Malignancy and lymphoid proliferation in primary immune deficiencies; hard to define, hard to treat , 2019, Pediatric blood & cancer.
[3] O. Haas. Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework , 2019, Front. Immunol..
[4] A. Frolov,et al. Spontaneous remission in diffuse large cell lymphoma: a case report , 2019, Journal of Medical Case Reports.
[5] Zhuoxuan Lu,et al. Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes , 2018, Oncoimmunology.
[6] L. Zitvogel,et al. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics , 2017, Oncoimmunology.
[7] T. Crawford,et al. Ataxia telangiectasia: a review , 2016, Orphanet Journal of Rare Diseases.
[8] B. Johnston,et al. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies , 2015, Oncotarget.
[9] H. Harada,et al. Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report. , 2015, Journal of clinical and diagnostic research : JCDR.
[10] A. Salem,et al. Three Steps to Breaking Immune Tolerance to Lymphoma: A Microparticle Approach , 2015, Cancer Immunology Research.
[11] M. Chao. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies , 2013, Cancer management and research.
[12] T. Morio,et al. Successful treatment of diffuse large B-cell lymphoma in a patient with ataxia telangiectasia using rituximab. , 2013, Journal of pediatric hematology/oncology.
[13] M. D. Del Bigio,et al. Ataxia-Telangiectasia: Atypical Presentation and Toxicity of Cancer Treatment , 2009, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[14] P. Byrd,et al. Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene , 2008, Clinical and experimental immunology.
[15] N. Nakamura,et al. Spontaneous regression of diffuse large B-cell lymphoma harbouring Epstein-Barr virus: a case report and review of the literature. , 2007, Journal of clinical and experimental hematopathology : JCEH.
[16] R. Gatti,et al. Ataxia-telangiectasia, an evolving phenotype. , 2004, DNA repair.
[17] D. Federman,et al. The epidemiology of non-Hodgkin's lymphoma. , 1996, Connecticut medicine.